Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dupilumab relieves severe sinusitis with polyposis

Key clinical point: Dupilumab met its primary efficacy and safety endpoints in a pivotal trial for treating chronic sinusitis with nasal polyps.

Major finding: After 24 weeks, the endoscopic nasal polyp score averaged a clinically meaningful 2.06 points lower on dupilumab, compared with placebo.

Study details: SINUS-24, a multicenter randomized trial with 276 patients.

Disclosures: SINUS-24 was funded by Regeneron and Sanofi, the companies that market dupilumab (Dupixent). Dr. Han has been an adviser to Regeneron and Sanofi.


Han JK et al. AAAAI, Abstract L4.